首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives
【24h】

Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives

机译:二氢氨基氨基氨基酸酯衍生物的合成与体外抗肿瘤评价

获取原文
获取原文并翻译 | 示例
           

摘要

To explore novel high efficiency and low toxicity antitumor agents, a series of dihydroartemisinin-cinnamic acid ester derivatives modified on C-12 and/or C-9 position (s) were synthesized and the in vitro antitumor activities against PC-3, SGC-7901, A549 and MDA-MB-435s cancer cell lines were assessed. The hybrids (3-36) were prepared by esterification of 9 alpha-hydroxyl-dihydroartemisinin (9 alpha-OH DHA), the biotransformation product of dihydroartemisinin (DHA), and cinnamic acid derivatives. Compound 17 (IC50 = 0.20 mu M) was the most potent anti-proliferative agent against the human lung carcinoma A549 cells, although it displayed low cytotoxicity on normal hepatic L-02 cells. The mechanism of action of compound 17 was further investigated by analysis of cell apoptosis and intracellular ROS generation. The results indicated that both ROS and ferrous ion contributed to the compound 17-induced cell death. Meanwhile, high intracellular ferrous ion and endogenous oxidative stress in A549 cells made them easier to suffer to compound 17-induced apoptosis. Our promising findings indicated the compound 17 could stand as drug candidate against lung cancer for further investigation. (C) 2015 Elsevier Masson SAS. All rights reserved.
机译:探索新的高效率和低毒性抗肿瘤剂,一系列修改的第C-12和/或C-9位置(S)的合成二氢青蒿素 - 肉桂酸的酯衍生物的以及在针对PC-3,SGC-体外抗肿瘤活性7901,评估A549和MDA-MB-435S癌细胞系。杂交(3-36)通过酯化的酯化为9α-羟基 - 二氢半体蛋白(9α-OH DHA),二羟基氨基蛋白(DHA)的生物转换产物和肉桂酸衍生物制备。化合物17(IC50 =0.20μm)是对人肺癌A549细胞的最有效的抗增殖剂,尽管它在正常肝脏L-02细胞上显示出低细胞毒性。通过分析细胞凋亡和细胞内ROS产生进一步研究化合物17的作用机制。结果表明,ROS和亚铁离子均导致化合物17诱导的细胞死亡。同时,A549细胞中的高细胞内亚铁离子和内源性氧化应激使其更容易遭受化合物17诱导的细胞凋亡。我们有前途的发现表明,化合物17可以抵抗肺癌的毒品候选者进一步调查。 (c)2015年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号